Summary
Pfizer Inc. reported a significant increase in total revenues for the third quarter of 2024, reaching $17.7 billion, a 31% rise compared to the prior year period. This growth was primarily driven by strong performance in Paxlovid, revenues from newly acquired Seagen products, and the Vyndaqel family, which more than offset declines in other areas. The company's net income attributable to Pfizer Inc. common shareholders was $4.465 billion, a substantial improvement from a net loss in the same quarter last year, largely due to increased revenues and a significant decrease in the cost of sales. This strong financial performance reflects a strategic shift towards oncology and growth in key therapeutic areas, alongside successful integration of recent acquisitions. For the first nine months of 2024, total revenues saw a modest increase to $45.9 billion. The company continues to focus on operational efficiency and cost realignment, with significant restructuring programs underway aimed at optimizing costs and improving margins. Despite ongoing investments in research and development and integration costs from acquisitions, Pfizer demonstrated a robust recovery in profitability, with income from continuing operations before taxes showing a substantial increase year-over-year. The company maintains a strong liquidity position, supported by robust operating cash flows and access to credit facilities, positioning it to continue investing in its pipeline and delivering value to shareholders.
Financial Highlights
54 data points| Revenue | $17.70B |
| Cost of Revenue | $5.26B |
| Gross Profit | $12.44B |
| SG&A Expenses | $3.24B |
| Interest Expense | $783.00M |
| Net Income | $4.46B |
| EPS (Basic) | $0.79 |
| EPS (Diluted) | $0.78 |
| Shares Outstanding (Basic) | 5.67B |
| Shares Outstanding (Diluted) | 5.71B |
Key Highlights
- 1Total revenues for Q3 2024 surged by 31% to $17.7 billion, driven by strong performance of Paxlovid, Seagen products, and the Vyndaqel family.
- 2Net income attributable to Pfizer Inc. common shareholders was $4.465 billion for Q3 2024, a significant turnaround from a net loss in the prior year quarter.
- 3Cost of sales decreased substantially by 43% to $5.26 billion in Q3 2024, largely due to the non-recurrence of significant inventory write-offs from the prior year.
- 4The company successfully integrated Seagen, contributing to revenue growth, and continues to manage costs through enterprise-wide realignment and manufacturing optimization programs.
- 5Research and development expenses saw a slight decrease, reflecting cost management while continuing to invest in key product candidates, including those from the Seagen acquisition.
- 6Pfizer maintained a strong liquidity position, with significant cash and cash equivalents and available credit facilities, supporting ongoing operations and strategic investments.
- 7The company provided updates on its robust product pipeline, including recent approvals and ongoing late-stage clinical programs across various therapeutic areas.